8 results about "Cholestasis" patented technology

The present application provides a compound of formula (I), or an optical isomer thereof, a pharmaceutically acceptable salt, a solvated form, or a prodrug. The compound may modulate NTCP function for the prevention and / or treatment of HBV / HDV and hepatitis virus-related diseases, bile acid-related cholestasis disorders, metabolic disorders, and / or liver diseases. Additionally, the present application relates to a pharmaceutical composition comprising such a compound and a method for modulating NTCP.

The application discloses application of AML-12 exosomes in preparation of medicines for treating cholestatic liver injury, relates to the technical field of biological medicine, and discloses application of AML-12 cell-derived exosomes in preparation of medicines for preventing and treating ANIT-induced cholestatic liver injury; the treatment is manifested as reduction of alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase levels in serum. The application proves that the AML-12 cell-derived exosomes have a significant treatment effect on ANIT-induced cholestatic liver injury, successfully opens up the application of the biological preparation in a brand-new disease field, and fills the blank of the prior art; through in-vivo experiments, it is proved that AML-12 exosome treatment can significantly reduce liver cell injury markers and alkaline phosphatase, a key index of cholestasis, in serum of ANIT model mice, and improve pathological injury of liver tissue, thereby constituting a complete curative effect evidence chain from function to morphology.

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg / kg / day.

This invention discloses a veterinary drug composition containing Bupleurum chinense extract, its preparation method, and its application, belonging to the technical field of veterinary traditional Chinese medicine preparations. The composition consists of active ingredients (only saikosaponins a and d, in a mass ratio of 0.8–1.2:1, accounting for 5%–50% of the total content) and excipients (one or more of microcrystalline cellulose, magnesium stearate, and starch). The dosage form is tablets, granules, or powder, with each unit dose containing 5–20 mg of the total mass of both. In preparation, dried Bupleurum chinense roots are pulverized and enzymatically hydrolyzed with a 1:1 complex enzyme, ultrasonically extracted with an ethanol-sodium citrate mixture, purified with AB-8 macroporous resin, and freeze-dried to obtain saikosaponin powder. This powder is then mixed with the excipients and granulated, tableted, or packaged into the corresponding dosage form. This composition shows significant efficacy against fatty liver in chickens, hepatitis in pigs, and cholestasis in ducks, exhibiting stability, high purity, and high efficiency, providing a safe new option for the treatment of liver and gallbladder diseases in livestock and poultry.

The present disclosure relates to compounds of the general formula (I):wherein R1, R2, R3, R4, R5, R6, and R7 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, a glyceride, an anhydride, a phospholipid, a carboxamide, a phospholipid, or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to metabolic diseases and liver diseases, such as non-alcoholic fatty liver disease and cholestasis diseases.

This invention discloses the application of leonurin in the preparation of drugs for reducing serum total bilirubin levels, belonging to the field of traditional Chinese medicine technology. Through the construction of different types of hyperbilirubin animal models, this invention is the first to discover that leonurin can significantly reduce serum total bilirubin levels, and can be used to treat hyperbilirubinemia, alleviate bilirubin elevation caused by cholestasis, and treat acute abnormal bilirubin elevation. Simultaneously, leonurin does not cause abnormalities in liver function indicators such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) during the bilirubin-lowering process, demonstrating good safety. This invention also provides a pharmaceutical composition containing leonurin and its preparation method. This invention provides a new drug option for the treatment of hyperbilirubinemia.

RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the AAT RNAi agent(s) to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure. 20 24 20 36 61 31 M ay 2 02 4 A B S T R A C T 2 0 2 4 2 0 3 6 6 1 3 1 M a y 2 0 2 4